Zhenyuan Wang,ab Mi Wang, *a Qingsheng Tao,c Yufei Li, d Hao Wang,a Mei Zhang,c Xueli Liuc and Jiaheng Zhang *a
a Sauvage Laboratory for Smart Materials, School of Materials Science and Engineering, Harbin Institute of Technology (Shenzhen), Shenzhen 518055, China. E-mail: 该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。, 该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。
b Shenzhen Shinehigh Innovation Technology Co., Ltd., Shenzhen 518055, China
c Advanced Research, L'Oreal Research & Innovation China, Shanghai 201206, China
d The Centre in Artificial Intelligence Driven Drug Discovery, Faculty of Applied Sciences, Macao Polytechnic University, Macao 999078, China
† Electronic supplementary information (ESI) available. CCDC 2101906. For ESI
and crystallographic data in CIF or other electronic format see DOI: https://doi.
org/10.1039/d5md00001g
Salicylic acid (SA) is a natural lipophilic active ingredient commonly used in cosmetics and skin disease treatments, offering benefits such as exfoliation, anti-inflammation effects, antibacterial properties, oil control, and acne alleviation. However, its poor water solubility, low bioavailability, and potential side effects, such as allergies, irritation, and dryness, hinder its widespread application. In this study, we prepared a betaine–salicylic acid (BeSA) cocrystal and systematically characterized its crystal structure, biological activity, and clinical efficacy. The results showed that BeSA has significantly lower irritancy and cytotoxicity than SA, but exhibits excellent anti-inflammatory and antioxidant properties as well as high moisturizing and anti-acne efficacy, making it a potential alternative to SA. Further, quantum chemical calculations and molecular docking simulations were conducted to investigate the intrinsic mechanisms underlying the excellent bioactivity of BeSA cocrystals. This study introduces an innovative solution for safer and more effective skincare formulations based on SA and offers theoretical guidance regarding material engineering and further material optimization, which has crucial implications for both industry and academia.
Received 1st January 2025,
Accepted 4th February 2025
DOI: 10.1039/d5md00001g rsc.li/medchem
Anna Ericsson a,* , Karin Borgstrom¨ b,c , Christine Kumlien a,c,d , Magdalena Gershater Annersten a,c , Tautgirdas Ruzgas b,c , Johan Engblom b,c , Petri Gudmundsson b,c , Victoria Lazer a , Skaidre Jankovskaja b,c , Eva Lavant b,c , Sophia Ågren-Witteschus d , Sebastian Bjorklund ¨ b,d , Saman Salim e,f , Mikael Åstrom¨ g , Stefan Acosta f
a Department of Care Science, Faculty of Health and Society, Malm¨ o University, Malm¨ o, Sweden
b Department of Biomedical Science, Faculty of Health and Society, Malm¨ o University, Malm¨ o, Sweden
c Biofilms – Research Center for Biointerfaces, Malm¨ o University, Malm¨ o, Sweden
d Department of Cardiothoracic and Vascular Surgery, Skåne University Hospital, Malm¨ o, Sweden
e Department of Dermatology and Allergy Centre, Odense University Hospital, Odense, Denmark
f Department of Clinical Sciences, Lund University, Malmo, ¨ Sweden
g StatCons, Sweden
ARTICLE INFO
Keywords: Diabetes mellitus Dry feet Prevention Foot-xerosis Self-care
ABSTRACT
Introduction: To minimize the risk of developing foot-ulcers, persons with diabetes are given the advice to daily inspect their feet and to apply skincare formulations. However, commercially available skincare products have rarely been developed and evaluated for diabetes foot care specifically. The primary aim of this randomized controlled trial (RCT) is to evaluate the effects in reducing foot xerosis in persons with diabetes without footulcers using two skincare creams containing different humectants (interventions) against a cream base nonhumectant (comparator). Secondary outcomes are to evaluate differences on skin barrier integrity, lowmolecular weight biomarkers and skin microbiota, microcirculation including transcutaneous oxygen pressure, degree of neuropathy, and HbA1c between intervention-comparator creams.
Methods: Two-armed double-blind RCT, registered in ClinicalTrials.gov Identifier: NCT06427889. With 80 % power, two-tailed significance of 2.5 % in each arm, 39 study persons is needed in each arm, total 78 persons, 98 including dropouts, to be able to prove a reduction of at least one category in the Xerosis Severity Scale with the intervention creams compared to the comparator. In one arm, each participant will treat one foot with one of the intervention creams (Oviderm® or Canoderm®), while the opposite foot will be treated with the comparator cream (Decubal®lipid cream), twice a day. If needed, participants are enrolled after a wash-out period of two weeks. The participants will undergo examinations at baseline, day 14 and day 28.
Discussion: This RCT evaluate the potential effects of humectants in skin creams against foot xerosis in persons with diabetes.
擅长：1. 烧伤/烫伤/手术疤痕美学修复; 2. 创面/伤口/溃疡/皮肤缺损美学修复; 3. 全身体表肿瘤/包块手术治疗。
擅长疾病：1.面部轮廓整形;2.面部年轻化;3.身体塑形;4.先天性和创伤后畸形修复、体表肿瘤切除及器官再造。如：黄褐斑、瘢痕疙瘩、减肥 。教授，整形外科副主任，医学博士后，毕业于西安第四军医大学临床医学系，毕业后留校。
在成人大面积烧伤的休克复苏、感染防治、多器官功能障碍综合征的防治、严重电烧伤和吸入性损伤的救治以及小儿重度和特重度烧伤的救治等方面有较高造诣。获黑龙江省科技进步三等奖2项，哈尔滨市科技进步二等奖1项，三等奖2项。
担任欧洲糖尿病学会会员、美国糖尿病学会会员、欧洲糖尿病学会糖尿病足研究组发起会员、中华医学会糖尿病学分会第2届足病学组组长、中国人民解放军内分泌学会副主任委员、北京内分泌学会副主任委员、北京糖尿病防治协会副理事长、北京市朝阳区预防医学会副会长、国家卫生部全国慢性病综合防治示范点专家组成员、中国疾病控制中心慢病中心糖尿病专家、第四军医大学兼职教授，悉尼大学客座教授，第四军医大学硕士研究生导师，中南大学湘雅三医院硕士研究生导师主任医师。
擅长诊治各种危急重症烧伤、烧伤后疤痕挛缩、功能畸形整复、各类急慢性伤口、复杂难愈性创面、伤口早期微创美容及早期抗疤治疗等
浙江大学临床医学二系教授，浙江大学医学院附属第二医院主任医师，毕业于日本金泽医科大学。
伤口世界平台生态圈，以“关爱人间所有伤口患者”为愿景，连接、整合和拓展线上和线下的管理慢性伤口的资源，倡导远程、就近和居家管理慢性伤口，解决伤口专家的碎片化时间的价值创造、诊疗经验的裂变复制、和患者的就近、居家和低成本管理慢性伤口的问题。
2019广东省医疗行业协会伤口管理分会年会
扫一扫了解详情:
任何关于疾病的建议都不能替代执业医师的面对面诊断。所有门诊时间仅供参考，最终以医院当日公布为准。
网友、医生言论仅代表其个人观点，不代表本站同意其说法，请谨慎参阅，本站不承担由此引起的法律责任。
